Search Results

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the first quarter ended March 31, 2024.

Leap Therapeutics, Inc. today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock (“Common Stock”) at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the fourth quarter and year ended December 31, 2023.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the third quarter ended September 30, 2023.

Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Leap Therapeutics, Inc. announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap’s anti-Dickkopf-1 antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer, to be presented at the upcoming 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium taking place in San Francisco, CA and virtually on January 18-20, 2024.

Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Leap Therapeutics, Inc. today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01.